Gregory R. Pond

23.0k total citations · 2 hit papers
575 papers, 15.8k citations indexed

About

Gregory R. Pond is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Gregory R. Pond has authored 575 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 242 papers in Pulmonary and Respiratory Medicine, 242 papers in Oncology and 117 papers in Surgery. Recurrent topics in Gregory R. Pond's work include Prostate Cancer Treatment and Research (86 papers), Bladder and Urothelial Cancer Treatments (52 papers) and Cancer Treatment and Pharmacology (48 papers). Gregory R. Pond is often cited by papers focused on Prostate Cancer Treatment and Research (86 papers), Bladder and Urothelial Cancer Treatments (52 papers) and Cancer Treatment and Pharmacology (48 papers). Gregory R. Pond collaborates with scholars based in Canada, United States and Italy. Gregory R. Pond's co-authors include Cynthia S. Crowson, Sherine E. Gabriel, Michele F. Doran, Lillian L. Siu, Ian F. Tannock, W. Michael O’Fallon, Mario A. Eisenberger, Ronald de Wit, Dominik Berthold and Eric X. Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Gregory R. Pond

547 papers receiving 15.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study

2002 896 citations Gregory R. Pond et al. profile →
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

2008 820 citations Gregory R. Pond et al. profile →

Peers

Countries citing papers authored by Gregory R. Pond

Since Specialization

Citations

This map shows the geographic impact of Gregory R. Pond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory R. Pond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory R. Pond more than expected).

Fields of papers citing papers by Gregory R. Pond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory R. Pond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory R. Pond. The network helps show where Gregory R. Pond may publish in the future.

Co-authorship network of co-authors of Gregory R. Pond

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory R. Pond. A scholar is included among the top collaborators of Gregory R. Pond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory R. Pond. Gregory R. Pond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis 2025 ·eJHaem ·(unknown), Dong An, Gregory R. Pond, Tobias Berg, (unknown), (unknown), (unknown), Graeme Fraser, Ronan Foley, (unknown)	0
2	Does Facilitated Palliative Care Education Improve Patient Identification? A Cluster Randomized Controlled Trial of Primary Care Providers in the CAPACITI Training Program 2025 ·Journal of Palliative Medicine ·Hsien Seow, Daryl Bainbridge, (unknown), Jeff Myers, Katherine Kortes-Miller, (unknown), Oren Levine, (unknown), (unknown), Gregory R. Pond, Denise Marshall, Kelli Stajduhar, José Pereira	1
3	Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy 2024 ·BMC Cancer ·(unknown), Gregory R. Pond, (unknown), Graeme Fraser, (unknown), Mark N. Levine, (unknown), Ronan Foley	1
4	Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy 2024 ·Radiation Oncology ·(unknown), Gregory R. Pond, (unknown), (unknown), Elham Ahmadi, (unknown), (unknown), Anand Swaminath, Gordon Okawara, Peter Ellis, Bassam Abdulkarim, (unknown), Andrew Robinson, Wilson Roa, Mario J. Valdés, Peter A. Kavsak, Marcin Wierzbicki, James Wright, Gregory R. Steinberg, Theodoros Tsakiridis	3
5	Patterns of Survivorship Follow-Up Care Among Patients With Breast Cancer: A Retrospective Population-Based Cohort Study in Ontario, Canada, Between 2006 and 2016 2024 ·JCO Oncology Practice ·Jonathan Sussman, Joshua O. Cerasuolo, Gregory R. Pond, Daryl Bainbridge, Hsien Seow	1
6	Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use 2024 ·Current Oncology ·(unknown), Gregory R. Pond, Elaine McWhirter	3
7	A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer 2024 ·Current Oncology ·Sharon F. McGee, Mark Clemons, Gregory R. Pond, Jean-Michel Caudrelier, (unknown), (unknown), Terry L. Ng, Arif Awan, Sandeep Sehdev, John Hilton, (unknown), Lesley Fallowfield, (unknown), Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean‐Marc Bourque	2
8	A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer 2023 ·Current Oncology ·Ricardo Fernandes, Terry L. Ng, (unknown), Jacques Raphael, Phillip Blanchette, (unknown), Carol Stober, Gregory R. Pond, David Cella, Lisa Vandermeer, Mohammed Ibrahim, Mark Clemons	3
9	Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study 2023 ·Blood ·Alissa Visram, Hsien Seow, Gregory R. Pond, (unknown), Arleigh McCurdy, (unknown), (unknown), C. Tom Kouroukis, Mohammed A. Aljama, (unknown), S.R. Foley, Hira Mian	1
10	SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma 2023 ·Clinical Cancer Research ·Lisa A. Kottschade, Gregory R. Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo‐Musibay, Ralph J. Hauke, Brendan D. Curti, (unknown), Mohammed Milhem, Matthew S. Block, Tina J. Hieken, Robert R. McWilliams	7
11	Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance 2023 ·International Journal of Molecular Sciences ·Elham Ahmadi, (unknown), (unknown), (unknown), (unknown), (unknown), Brent E. Faught, Jean‐Claude Cutz, Monalisa Sur, (unknown), Gregory R. Pond, Gregory R. Steinberg, Ian H. Brown, Theodoros Tsakiridis	2
12	Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center 2023 ·JCO Clinical Cancer Informatics ·Jeremy Petch, (unknown), Christopher Pettengell, (unknown), (unknown), Gregory R. Pond, Ashirbani Saha, Jessica Bogach, (unknown), (unknown), Jonathan Ranisau, Mark N. Levine	5
13	Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer 2023 ·Cancers ·Huijun Zhao, Gregory R. Pond, Demetrios Simos, Zhou Wang, Susan J. Robertson, Gurmit Singh, Lisa Vandermeer, Mark Clemons, Christina Addison	3
14	Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease 2021 ·Heart ·Darryl P. Leong, Nazanin Aghel, Christopher Hillis, Deborah Siegal, Sarah Karampatos, Sumathy Rangarajan, Gregory R. Pond, Hsien Seow	12
15	High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer 2020 ·Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Gregory R. Pond, Juliet M. Daniel	8
16	Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer 2019 ·Cancer ·Guru Sonpavde, Neeraj Agarwal, Gregory R. Pond, Rebecca J. Nagy, Roberto Nussenzveig, Andrew W. Hahn, Oliver Sartor, Theodore Stewart Gourdin, Lakshminarayanan Nandagopal, Elisa M. Ledet, Gurudatta Naik, Andrew J. Armstrong, Jue Wang, Mehmet Asım Bilen, Shilpa Gupta, Petros Grivas, Sumanta K. Pal, Richard B. Lanman, AmirAli Talasaz, Michelle M. Lilly	41
17	Outcome analysis of visual acuity and side effect after ruthenium-106 plaque brachytherapy for medium-sized choroidal melanoma 2018 ·Middle East African Journal of Ophthalmology ·(unknown), (unknown), Gregory R. Pond, Jean Deschênes	7
18	Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer 2016 ·Clinical Lung Cancer ·David E. Dawe, Gregory R. Pond, Peter Ellis	22
19	Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials 2011 ·Clinical Trials ·Gregory R. Pond, Saqib Abbasi	18
20	Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors 2006 ·Cancer Research ·Aaron D. Schimmer, Michael P. Thomas, Rose Hurren, Marcela Gronda, Maurizio Pellecchia, Gregory R. Pond, Marina Konopleva, Debbie Gurfinkel, Imtiaz A. Mawji, Ewan Brown, John C. Reed	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact